Finally, an exploratory of the ECHELON‐2 trial was conducted, for the 82 patients with a declared intention to transplant out of the 177 patients randomized to BV‐CHP arm (ALK‐positive ALCL were excluded). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.